Presentation of the annual report with auditors’ report for adoption
The AGM resolved in accordance with the Board of Directors’ proposal, to approve the annual report presented during the AGM.

Resolution concerning the appropriation of profits or losses as recorded in the adopted annual report
The AGM resolved, in accordance with the Board of Directors’ proposal, that the result for the period 1 October 2020 – 30 September 2021 (DKK 647,626) is carried forward to the following year.

Election of members to the board of directors
The AGM resolved, in accordance with the Board of Directors’ proposal, that the Board members were re-elected..

Election of auditor
The AGM resolved, in accordance with the board of directors’ proposal, that the existing auditor Christensen Kjærulff Statsautoriseret Revisionsaktieselskab was re-elected.

Change of the Company’s signatory rule
The AGM resolved, in accordance with the board of directors proposal, that the signatory rule in clause 8.1 of the articles of association is changed from:

"The Company is bound by the joint signatures of the CEO and the chairman, by four members of the board of directors or by the chairman and two members of the board of directors."

to:

"The Company is bound by the joint signatures of the CEO and one member of the board of directors, by three members of the board of directors or by the entire board of directors."

Change of clause 5.9 in the articles of association
The AGM resolved, in accordance with the board of directors proposal, that "VP Investor Services A/S" is changed to the "Company" in clause 5.9 in the articles of association, whereupon clause 5.9 reads:

"Any shareholder who has requested an admission card no later than two days before the general meeting or has sent an instrument appointing a proxy so that it is received by the Company no later than two days before the general meeting will be entitled to attend the meeting. Shareholders unable to attend may vote by postal ballot. The postal ballot must be received by the Company no later than 4.00 pm on the day before the general meeting."

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on 09-12-2021 16:54 CET.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: "CSMED"). For more information about CS MEDICA cs-medica.com.